Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 6/2012

01-12-2012 | TASK FORCE REPORT

Indian Society of Gastroenterology consensus on ulcerative colitis

Authors: Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan, for Indian Society of Gastroenterology Task Force on Inflammatory Bowel Diseases

Published in: Indian Journal of Gastroenterology | Issue 6/2012

Login to get access

Abstract

In 2010, the Indian Society of Gastroenterology’s Task Force on Inflammatory Bowel Diseases undertook an exercise to produce consensus statements on ulcerative colitis. This consensus, produced through a modified Delphi process, reflects our current understanding of the definition, diagnostic work up, treatment and complications of ulcerative colitis. The consensus statements are intended to serve as a reference point for teaching, clinical practice, and research in India.
Literature
1.
2.
3.
Periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J. 1984;130:1278–85.
4.
Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef
5.
Khosla SN, Girdhar NK, Lal S, Mishra DS. Epidemiology of ulcerative colitis and select general population of northern India. J Assoc Physicians India. 1986;34:405–7.PubMed
6.
Sood A, Midha V, Sood N, et al. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52:1587–90.PubMedCrossRef
7.
Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–9.PubMedCrossRef
8.
Lok KH, Hung HG, Ng CH, et al. Epidemiology and clinical characteristics of ulcerative colitis in Chinese population: experience from a single center in Hong Kong. J Gastroenterol Hepatol. 2008;23:406–10.PubMedCrossRef
9.
Chow DK, Leong RW, Tsoi KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009;104:647–54.PubMedCrossRef
10.
Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol. 1995;30 Suppl 8:1–4.
11.
Lee YM, Fock K, See SJ, Ng TM, Khor C, Teo EK. Racial differences in the prevalence of ulcerative colitis and Crohn’s disease in Singapore. J Gastroenterol Hepatol. 2000;15:622–5.PubMedCrossRef
12.
Ling KL, Ooi CJ, Luman W, Cheong WK, Choen FS, Ng HS. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. J Clin Gastroenterol. 2002;35:144–8.PubMedCrossRef
13.
Tan YM, Goh KL. Ulcerative colitis in a multiracial Asian country: racial differences and clinical presentation among Malaysian patients. World J Gastroenterol. 2005;11:5859–62.PubMed
14.
Probert CS, Mayberry JF, Mann R. Inflammatory bowel disease in the rural Indian subcontinent: a survey of patients attending mission hospitals. Digestion. 1990;47:42–6.PubMedCrossRef
15.
Maroo MK, Nag NK, Sortur SV, Patil RS. Ulcerative colitis in Southern Maharashtra. J Indian Med Assoc. 1974;63:350–4.PubMed
16.
Tandon BN, Mathur AK, Mohapatra LN, Tandon HD, Wig KL. A study of the prevalence and clinical pattern of non-specific ulcerative colitis in northern India. Gut. 1965;6:448–53.PubMedCrossRef
17.
Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol. 2007;26:285–9.PubMed
18.
Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut. 1994;35:696–700.PubMedCrossRef
19.
Jiang L, Xia B, Li J, et al. Risk factors for ulcerative colitis in a Chinese population: an age-matched and sex-matched case–control study. J Clin Gastroenterol. 2007;41:280–4.PubMedCrossRef
20.
Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol. 1995;30 Suppl 8:5–8.
21.
Park JB, Yang SK, Byeon JS, et al. Familial occurrence of inflammatory bowel disease in Korea. Inflamm Bowel Dis. 2006;12:1146–51.PubMedCrossRef
22.
Probert CS, Jayanthi V, Hughes AO, Thompson JR, Wicks AC, Mayberry JF. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34:1547–51.PubMedCrossRef
23.
Probert CS, Jayanthi V, Pinder D, et al. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33:687–93.PubMedCrossRef
24.
Carr I, Mayberry JF. The effects of migration on ulcerative colitis: a three-year prospective study among Europeans and first and second-generation South Asians in Leicester (1991–1994). Am J Gastroenterol. 1999;94:2918–22.PubMed
25.
Jayanthi V, Probert CS, Pollock DJ, et al. Low incidence of ulcerative colitis and proctitis in Bangladeshi migrants in Britain. Digestion. 1992;52:34–42.PubMedCrossRef
26.
Probert CS, Jayanthi V, Mayberry JF. Inflammatory bowel disease in Indian migrants in Fiji. Digestion. 1991;50:82–4.PubMedCrossRef
27.
Rajput HI, Seebaran AR, Desai Y. Ulcerative colitis in the Indian population of Durban. S Afr Med J. 1992;81:245–8.PubMed
28.
Kochhar R, Mehta SK, Nagi B, Bhatia V, Goenka MA, Malik AK. Extraintestinal manifestations in idiopathic ulcerative colitis. Indian J Gastroenterol. 1991;10:88–9.PubMed
29.
Pokharna RK, Kabra PK, Sharma P, Kochar DK. Extraintestinal manifestations of idiopatic ulcerative colitis in north western India. Indian J Gastroenterol. 2004;123:89–90.
30.
Chandrasekaran AN, Porkodi R, Madhavan R, Sambandam PR, Jayanthi V, Ramathilagam B. Spectrum of clinical and immunological features of systemic rheumatic disorders in a referral hospital in south India: arthritis in ulcerative colitis. J Indian Rheumat Assoc. 1995;3:43–7.
31.
Habeeb MA, Rajalingam R, Dhar A, Kumar A, Sharma MP, Mehra NK. HLA association and occurrence of autoantibodies in Asian patients with ulcerative colitis. Am J Gastroenterol. 1997;92:772–6.PubMed
32.
Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.PubMedCrossRef
33.
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16.
34.
Stange EF, Travis SP, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis. 2008;2:1–23.CrossRef
35.
Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–68.PubMedCrossRef
36.
Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation. Gastrointest Endosc. 1983;29:195–7.PubMedCrossRef
37.
Dunzendorfer T, Kasznica J. Amebic and/or ulcerative colitis? Gastrointest Endosc. 1998;48:450–1.PubMedCrossRef
38.
Misra SP, Misra V, Dwivedi M, Singh PA. Colonic tuberculosis mimicking ulcerative colitis. J Assoc Physicians India. 1998;46:309–10.PubMed
39.
Chodos JE. Campylobacter infection mimicking ulcerative colitis. NY State J Med. 1986;86:22–3.
40.
Ibrahim TM, Iheonunekwu N, Gill V, Vantapool H. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005;54:210–12.PubMedCrossRef
41.
Mann EA, Saeed SA. Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol. 2012;28:24–9.PubMedCrossRef
42.
Khuroo MS, Mahajan R, Zargar SA, et al. The colon in shigellosis: serial colonoscopic appearances in Shigella dysenteriae I. Endoscopy. 1990;22:35–8.PubMedCrossRef
43.
Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993;16:26–30.PubMedCrossRef
44.
Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–60.
45.
Banerjee D, Deb R, Dar L, et al. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44:325–31.PubMedCrossRef
46.
Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–8.PubMedCrossRef
47.
Vaishnavi C, Kochhar R, Bhasin D, Thennarasu K, Singh K. Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol. 2003;24:13–6.PubMed
48.
Kashyap B, Sinha S, Das S, Rustagi N, Jhamb R. Efficiency of diagnostic methods for correlation between prevalence of enteric protozoan parasites and HIV/AIDS status––an experience of a tertiary care hospital in East Delhi. J Parasit Dis. 2010;34:63–7.PubMedCrossRef
49.
Montes M, Sawhney C, Barros N. Strongyloides stercoralis: there but not seen. Curr Opin Infect Dis. 2010;23:500–4.PubMedCrossRef
50.
Navarro-Llavat M, Domènech E, Bernal I, et al. Prospective, observational, cross-sectional study of intestinal infections among acutely active inflammatory bowel disease patients. Digestion. 2009;80:25–9.PubMedCrossRef
51.
Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol. 2011;30:245–54.PubMedCrossRef
52.
Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–7.PubMedCrossRef
53.
Sung JJY, Kamm MA, Marteau P. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey. J Gastroenterol Hepatol. 2010;25:183–93.PubMedCrossRef
54.
Schusselé Filliettaz S, Juillerat P, Burnand B, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Chronic diarrhea and known inflammatory bowel disease. Endoscopy. 2009;41:218–26.PubMedCrossRef
55.
Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol. 2010;16:2600–3.PubMedCrossRef
56.
Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979–94.PubMedCrossRef
57.
Kochhar R, Goenka MK, Kaushik SP, Gupta NM, Nagi B, Mehta SK. Colorectal carcinoma in Indian patients with idiopathic ulcerative colitis. Eur J Cancer Prev. 1992;1:293–6.PubMedCrossRef
58.
Venkataraman S, Mohan V, Ramakrishna BS, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–9.PubMedCrossRef
59.
Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17:1008–14.PubMedCrossRef
60.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.PubMedCrossRef
61.
Naber AHJ, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003;61:105–10.PubMed
62.
Thia KT, Loftus EV Jr, Pardi DS, et al. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011;17:1257–64.PubMedCrossRef
63.
Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J Gastroenterol. 2009;28:143–6.PubMedCrossRef
64.
Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther. 2006;24 Suppl 3:41–4.
65.
Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263–76.PubMedCrossRef
66.
Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–81.PubMedCrossRef
67.
Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115.
68.
Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol. 1990;25:663–8.PubMedCrossRef
69.
D’Arienzo A, Panarese A, D’Armiento FP, et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol. 1990;85:1079–82.PubMed
70.
Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis. 1998;4:79–83.PubMedCrossRef
71.
Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left -sided ulcerative colitis. Gastroenterology. 1988;94:1075–9.PubMed
72.
Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):D000544.
73.
Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962;1:1094–6.PubMedCrossRef
74.
Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.
75.
Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009;15:1–8.PubMedCrossRef
76.
Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902.PubMedCrossRef
77.
Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–71.PubMed
78.
Faubion Jr WA, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–60.PubMedCrossRef
79.
Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J. 1962;2:1708–11.PubMedCrossRef
80.
Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, Salazopyrin and topicalhydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut. 1960;1:217–22.PubMedCrossRef
81.
Baron JH, Connell AM, Kanaghinis TG, et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J. 1962;2:441–3.PubMedCrossRef
82.
Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12:40–1.PubMedCrossRef
83.
Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–87.PubMedCrossRef
84.
Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;i:1067–70.CrossRef
85.
Turner D, Walsh C, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–10.PubMedCrossRef
86.
Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47–53.PubMedCrossRef
87.
Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(1):CD000478.
88.
Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512–8.PubMedCrossRef
89.
Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717–22.PubMed
90.
Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455–61.PubMedCrossRef
91.
Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37:270–4.PubMedCrossRef
92.
Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740–6.PubMedCrossRef
93.
Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22:79–81.PubMed
94.
Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006;12:7332–6.PubMed
95.
Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology. 2004;127:1558–64.PubMedCrossRef
96.
Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol. 2010;27:1046–9.PubMedCrossRef
97.
Kham SK, Tan PL, Tay AH, Heng CK, Yeoh AE, Quah TC. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2002;24:353–9.PubMedCrossRef
98.
Ashavaid TF, Raghavan R, Shah S, Kapadia A, Almel S, Desai D. TPMT and DPD polymorphisms: efficient screening method for Indian patients considering taking thiopurine and 5-FU drugs. Dis Markers. 2009;27:231–8.PubMed
99.
Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.PubMedCrossRef
100.
Van Assche G, D’Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.PubMedCrossRef
101.
Sood A, Midha V, Sood N, et al. Cyclosporine in the treatment of severe steroid refractory ulcerative colitis: a retrospective analysis of 24 cases. Indian J Gastroenterol. 2008;27:232–5.PubMed
102.
Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(3):CD005112.
103.
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef
104.
Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.PubMedCrossRef
105.
Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59:C4480.PubMed
106.
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974–6.PubMed
107.
Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13:1453–4.PubMedCrossRef
108.
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15:89–102.PubMed
109.
Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis. 2010;16:507–11.PubMed
110.
Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20–34.PubMedCrossRef
111.
Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C. The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011;46:855–61.PubMedCrossRef
112.
Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5:39.PubMedCrossRef
113.
Cima RR. Timing and indications for colectomy in chronic ulcerative colitis: Surgical consideration. Dig Dis. 2010;28:501–7.PubMedCrossRef
114.
Van Assche G, Vermeire S, Rutgeerts P. Management of acute severe ulcerative colitis. Gut. 2011;60:130–3.PubMedCrossRef
115.
Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut. 2011;60:3–9.PubMedCrossRef
116.
Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.PubMedCrossRef
117.
Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204:956–62.PubMedCrossRef
118.
Koltun WA. Role of medical rescue therapy in the management of acute severe ulcerative colitis: the surgical perspective. Expert Rev Gastroenterol Hepatol. 2009;3:325–7.PubMedCrossRef
119.
Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis. 2009;27:335–40.PubMedCrossRef
120.
Rao YG, Saxena R, Sahni P, Pande GK, Chattopadhyay TK. Functional outcome and patient satisfaction after ileal pouch anal anastomosis for ulcerative colitis in a developing country. Trop Gastroenterol. 2002;23:66–9.PubMed
121.
Somashekar U, Gupta S, Soin A, Nundy S. Functional outcome and quality of life following restorative proctocolectomy for ulcerative colitis in Indians. Int J Colorectal Dis. 2010;25:967–73.PubMedCrossRef
122.
Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol. 1999;94:1746–50.PubMedCrossRef
123.
Vleggaar FP, Lutgens MW, Claessen MM. Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26 Suppl 2:47–52.
124.
Thomas T, Nair P, Dronfield MW, Mayberry JF. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005;17:1317–24.PubMedCrossRef
125.
Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51 Suppl 5:V10–12.
126.
Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.PubMedCrossRef
127.
Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2003;1:465–73.PubMedCrossRef
128.
Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10.PubMedCrossRef
129.
Ezzat Y, Hamdy K. The frequency of low bone mineral density and its associated risk factors in patients with inflammatory bowel diseases. Int J Rheum Dis. 2010;13:259–65.PubMedCrossRef
130.
Navaneethan U, Shen L, Venkatesh PG, et al. Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients. J Crohns Colitis. 2011;5:415–22.PubMedCrossRef
131.
Shen B, Remzi FH, Oikonomou IK, et al. Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis. Am J Gastroenterol. 2009;104:639–46.PubMedCrossRef
132.
Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J Gastroenterol. 2008;27:103–6.PubMed
133.
Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr. 2004;23:161–70.PubMedCrossRef
134.
Bernstein CN, Ament M, Artinian L, Ridgeway J, Shanahan F. Milk tolerance in adults with ulcerative colitis. Am J Gastroenterol. 1994;89:872–7.PubMed
135.
Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot. 2011;74:801–11.PubMedCrossRef
136.
Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008;53:1278–84.PubMedCrossRef
137.
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–9.PubMedCrossRef
138.
Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;(4):CD005573.
139.
Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 2010;44:565–71.PubMedCrossRef
140.
Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRef
141.
Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–9.PubMedCrossRef
142.
Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–7.PubMedCrossRef
143.
Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol. 2006;5:187–9.PubMed
144.
Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968;1:117–8.PubMedCrossRef
145.
Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113–23.PubMedCrossRef
146.
Schirbel A, Sturm A. Imaging in inflammatory bowel disease: mucosal healing in ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012; May 28. [Epub ahead of print].
147.
Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004;20 Suppl 4:97–101.PubMedCrossRef
148.
Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008;14:4434–9.PubMedCrossRef
149.
Levine JS, Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis. 2007;13:1293–8.PubMedCrossRef
150.
Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008;6:1225–30.PubMedCrossRef
151.
Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731–6.PubMedCrossRef
152.
Ardizzone S, Porro GB. How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis? Inflamm Bowel Dis. 2008;14 Suppl 2:S238–9.PubMedCrossRef
153.
Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther. 2002;16 Suppl 4:21–4.PubMedCrossRef
154.
Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.
Metadata
Title
Indian Society of Gastroenterology consensus on ulcerative colitis
Authors
Balakrishnan S. Ramakrishna
Govind K. Makharia
Philip Abraham
Uday C. Ghoshal
Venkataraman Jayanthi
Brij Kishore Agarwal
Vineet Ahuja
Deepak K. Bhasin
Shobna J. Bhatia
Gourdas Choudhuri
Sunil Dadhich
Devendra C. Desai
Gopal Krishna Dhali
Bhaba Dev Goswami
Sanjeev K. Issar
Ajay K. Jain
Rakesh Kochhar
Ajay Kumar
Goundappa Loganathan
Sri Prakash Misra
C. Ganesh Pai
Sujoy Pal
Anna Pulimood
Amarender S. Puri
Ganesh N. Ramesh
Gautam Ray
Shivaram P. Singh
Ajit Sood
Manu Tandan
for Indian Society of Gastroenterology Task Force on Inflammatory Bowel Diseases
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Indian Journal of Gastroenterology / Issue 6/2012
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-012-0259-0

Other articles of this Issue 6/2012

Indian Journal of Gastroenterology 6/2012 Go to the issue

Editorial

Inflammatory bowel disease: the Indian augury

Image

Intestinal lipomatosis detected on CT

Original Article

Major liver resection without preoperative biliary drainage in jaundiced patients with hilar biliary obstruction

TASK FORCE REPORT

Survey of inflammatory bowel diseases in India

Image

Pseudolesion in a patient with superior vena cava syndrome

Image

Giant staghorn common bile duct calculus

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits